Ambition,
responsibility, care
Observe Medical is a fast growing medtech company currently most recognised for development and distribution of the Sippi automated digital urine system. Our vision is to enable innovations to be commercialised on a global market for the benefit of society, healthcare professionals and patients.
With Sippi, the company’s prevalent current focus is on addressing the challenge of hospital acquired infection in healthcare facilities worldwide. Urinary tract infections are the number one hospital acquired complication for patients, and their treatment is a considerable burden to hospital staff and budgets. Overall, almost 3 million Europeans are infected every year from hospital acquired infections of all types.
Observe Medical’s intent is to continually grow our platform and portfolio to address these and other healthcare challenges, through ongoing R&D and acquisition strategies in line with our goals and vision.
Management team

Björn Larsson
Chief Executive Officer
Broad experience from marketing and business development within medtech, pharmaceuticals and biotech, i.a. from ABIGO Medical, Dentsply, Medtronic, Mentice, AstraZeneca and Novo Nordisk.

PER ARNE NYGÅRD
Chief Financial Officer
Broad experience from finance functions in various industries. The last 12 years in listed companies as Veidekke and Multiconsult. Joined Navamedic as consultant in August 2019 and participated in the listing of Observe Medical.
Board of directors

TERJE BAKKEN
Chairman of the Board
Partner in Norwegian private equity company Reiten & Co, the largest shareholder in Navamedic Extensive experience from private equity, management and consulting

KATHRINE GAMBORG ANDREASSEN
Board member
Chief Executive Officer of Navamedic since 2018 Comprehensive experience from marketing and executive positions within consumer health, i.a. from Novicus Pharma, Weifa and Orkla

KRISTIN NYBERG
Board member
Governmental affairs / public affairs business consulting in Nyberg Consulting since 2019 Vast experience from the medical industry, i.a. from Biogen (Country Director Norway), Abbott, Photocure and Roche

THOMAS GRÜNFELD
Board member
Chief Executive Officer of Labrida since 2012, Faculty board member (external) at OsloMet University since 2016 Medical degree, with vast experience from the medical industry, management roles, consulting and investment management